Nanotoxicology and Remediation - Nanomaterials for Medical Applications - page 405

223. Davies, S.; Macnaghten, P.; Kearnes, M. Reconfiguring Responsibility: Lessons for Public
Policy (Part 1 of the report on Deepening Debate on Nanotechnology) . 2009.
224. Commission, E. Commission Recommendation on A Code of Conduct for Responsible Nano-
sciences and Nanotechnologies Research & Council Conclusions on Responsible Nanosci-
ences and Nanotechnologies Research . 2008. Available from: http://ec.europa.eu/research/
research-eu .
225. Bowman, D.; Hodge, G. Nanotechnology: Mapping the Wild Regulatory Frontier. Futures
2006, 38, 1060-1073.
226. Society, R. Nanoscience and Nanotechnologies: Opportunities and Uncertainties . 2004.
Available from: http://www.nanotec.org.uk/inalReport.htm .
227. Mee, W.; Katz, E.; Solomon, F.; Lovel, R. In PATH conference: Australia, 2006.
228. Dietrich, H.; Schibeci, R. Beyond Public Perceptions of Gene Technology: Community Par-
ticipation in Public Policy in Australia 2003, 12 .
229. Marchant, G.; Syvester, D. Transnational Models for Regulation of Nanotechnology. J. Law
Med. Ethics 2006, 34, 714-725.
230. TGA Safety of Sunscreens Containing Nanoparticles of Zinc Oxide or Titanium Dioxide .
2006.
231. Faunce, T. A.; Nasu, H.; Murray, K.; Bowman, D. Sunscreen Safety: The Precautionary Prin-
ciple, The Australian Therapeutic Goods Administration and Nanoparticles in Sunscreens.
Nanoethics 2008, 2, 231-240.
232. Barker, P. J.; Branch, A. The Interaction of Modern Sunscreen Formulations with Surface
Coatings. Progr. Organic Coatings 2008, 62, 313-320.
233. Vines, T.; Faunce, T. A. Assessing the Safety and Cost-effectiveness of Early Nanodrugs.
J. Law Med. 2007, 16, 822-845.
234. Faunce, T. A. Policy Challenges of Nanomedicine for Australia's PBS. Aust. Health Rev.
2009, 33, 258-267.
235. Faunce, T. A. Toxicological and Public Good Considerations for the Regulation of Nanomate-
rial-containing Medical Products. Expert. Opin. Drug. Safety 2008, 7, 103-106.
236. USFDA FDA Issues Draft Guidance on Nanotechnology Documents Address Use of Nano-
technology by Food and Cosmetics Industries . 2012. Available from: http://www.fda.gov/
Cosmetics/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/ucm300886.htm .
237. USFDA Cosmetics: Draft Guidance for Industry. Saf. Nanomat. Cosmet. Prod. 2012.
Available from: http://www.fda.gov/Cosmetics/GuidanceComplianceRegulatoryInformation/
GuidanceDocuments/ucm300886.htm .
238. USFDA Draft Guidance for Industry: Assessing the Effects of Significant Manufacturing Pro-
cess Changes, Including Emerging Technologies, on the Safety And Regulatory Status of Food
Ingredients and Food Contact Substances, Including Food Ingredients that are Color Addi-
tives . 2012.
239. SCENIHR. Risk Assessment of Products of Nanotechnologies, 2009. Directorate General for
Health Consumers, European Commision, pp. 71.
240. Wild, J. Patent Challenges for Nanotech Investors. Intellectual Asset Management 2003,
29-32.
241. USPTO. Class 977 Nanotechnology Cross-reference Art Collection . Accessed on June 24,
2012. Available from: http://www.uspto.gov/patents/resources/classiication/class_977_
nanotechnology_cross-ref_art_collection.jsp .
242. Koosha, A.; Ahmadi, M.; Nazifi, A.; Mousazadeh, R. Intellectual Property Rights of Nano-
Biotechnology in Trade Related Aspects of Intellectual Property Agreement (TRIPS). Indian
J. Sci. Tech. 2012, 5, 2436-2442.